Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Biosimilar race: Sandoz expands pipeline with Henlius, Teva secures ocrelizumab candidate

2 September 2026 · By · Wire by Fusion42

Published

2 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Global

◆ Source

Read at gabionline.net →

◆ Verified

Fusion42 · 2 September 2026 · Fusion42 review

Sandoz expanded its biosimilar portfolio through a strategic collaboration with Shanghai Henlius Biotech covering up to 10 monoclonal antibody assets, while Teva secured exclusive global commercialization rights for a biosimilar candidate to Ocrevus (ocrelizumab) via a licensing agreement with Polpharma Biologics.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face growing competition as major players lock up biosimilar candidates and commercialization rights early. If your biotech firm develops biosimilars, partner aggressively or risk losing key market opportunities ahead of upcoming patent expiries.

◆ Coverage

1 source · 2 Sep 2026

◆ Related on Wire

◆ Topics

Biotechbiosimilarspharma-collaborationmonoclonal-antibodiesdrug-developmentmarket-expansion